Intech Investment Management LLC Decreases Stock Holdings in CVS Health Corporation $CVS

Intech Investment Management LLC decreased its position in shares of CVS Health Corporation (NYSE:CVS) by 20.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,481 shares of the pharmacy operator’s stock after selling 10,397 shares during the period. Intech Investment Management LLC’s holdings in CVS Health were worth $2,743,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in CVS. ProShare Advisors LLC lifted its position in shares of CVS Health by 13.0% during the fourth quarter. ProShare Advisors LLC now owns 225,757 shares of the pharmacy operator’s stock valued at $10,134,000 after buying an additional 26,054 shares during the last quarter. Raiffeisen Bank International AG purchased a new stake in shares of CVS Health during the fourth quarter valued at about $377,000. Rafferty Asset Management LLC lifted its position in shares of CVS Health by 11.9% during the fourth quarter. Rafferty Asset Management LLC now owns 142,717 shares of the pharmacy operator’s stock valued at $6,407,000 after buying an additional 15,126 shares during the last quarter. Twinbeech Capital LP purchased a new stake in shares of CVS Health during the fourth quarter valued at about $62,073,000. Finally, Triglav Skladi D.O.O. purchased a new position in shares of CVS Health in the 4th quarter valued at approximately $7,904,000. 80.66% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the transaction, the director owned 22,156 shares of the company’s stock, valued at $1,573,519.12. This represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.22% of the stock is owned by insiders.

CVS Health Price Performance

Shares of NYSE CVS opened at $75.00 on Monday. The firm has a market cap of $95.12 billion, a PE ratio of 20.95, a PEG ratio of 0.83 and a beta of 0.62. The firm has a fifty day moving average of $67.11 and a 200 day moving average of $66.33. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. CVS Health Corporation has a one year low of $43.56 and a one year high of $75.55.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company had revenue of $98.92 billion during the quarter, compared to analyst estimates of $94.87 billion. During the same quarter in the previous year, the firm earned $1.83 EPS. The firm’s revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, July 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s payout ratio is presently 74.30%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. UBS Group upgraded CVS Health from a “neutral” rating to a “buy” rating and boosted their price target for the company from $67.00 to $79.00 in a research note on Monday, August 18th. Jefferies Financial Group raised their price target on shares of CVS Health from $74.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, June 30th. Barclays raised their price target on shares of CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research report on Thursday, September 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $78.00 price target on shares of CVS Health in a research report on Tuesday, August 26th. Finally, Zacks Research lowered shares of CVS Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $77.89.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.